[1]陈莉 杨艳峰.婴幼儿室上性心动过速药物治疗疗程管理及相关因素[J].心血管病学进展,2025,(4):310.[doi:10.16806/j.cnki.issn.1004-3934.2025.04.006]
　CHEN Li,YANG Yanfeng.Management of Treatment Duration and Associated Factors in Pharmacotherapy for Supraventricular Tachycardia in Infants and Young Children[J].Advances in Cardiovascular Diseases,2025,(4):310.[doi:10.16806/j.cnki.issn.1004-3934.2025.04.006]
点击复制

婴幼儿室上性心动过速药物治疗疗程管理及相关因素()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年4期
页码:
310
栏目:
综述
出版日期:
2025-04-25

文章信息/Info

Title:
Management of Treatment Duration and Associated Factors in Pharmacotherapy for Supraventricular Tachycardia in Infants and Young Children
作者:
陈莉 杨艳峰
(电子科技大学医学院附属妇女儿童医院 成都市妇女儿童中心医院心内科,四川 成都 611731)
Author(s):
CHEN Li; YANG Yanfeng
(Department of Pediatric Cardiology,Chengdu Womens and Childrens Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 611731,Sichuan,China)
关键词:
室上性心动过速婴幼儿药物治疗疗程管理影响因素
Keywords:
Supraventricular tachycardia; Infants and young children; Drug t; Treatment uration; Risk factors?
DOI:
10.16806/j.cnki.issn.1004-3934.2025.04.006
摘要:
婴幼儿室上性心动过速反复持续发作可能导致严重心功能不全，临床。具有临床特征的患儿，明确相关因素可以对患儿进行复发风险评估，并确定低复发风险的人群。低复发风险患儿给予，。
Abstract:
Recurrent and persistent episodes of supraventricular tachycardia in infants and young children may lead to severe cardiac dysfunction. Although current clinical guidelines recommend long-term pharmacological management, the correlation between treatment duration and risk stratification requires further investigation. Specific pediatric populations with distinct clinical characteristics demonstrate substantially elevated recurrence risks. Identification of these predictive factors enables precise recurrence risk evaluation and facilitates the delineation of low-risk subgroups. For patients stratified as low recurrence risk, implementing a 4 to 6 month short-term pharmacological intervention strategy achieves equivalent recurrence control rates while significantly reducing the incidence of drug-related adverse events compared with extended treatment protocols

参考文献/References:

[1] Bücking C,Michaelis A,Markel F,et al. Evaluation of clinical course and maintenance drug treatment of supraventricular tachycardia in children during the first years of life. a cohort study from eastern germany[J]. Pediatr Cardiol,2022,43(2):332-343.
[2] Bjelo?evi? M,Illíková V,Tomko J,et al. Supraventricular tachyarrhythmias during the intrauterine,neonatal,and infant period:a 10-year population-based study[J]. Pacing Clin Electrophysiol,2020,43(7):680-686.?
[3] Leoni L,Bronzetti G,Colonna D,et al. Diagnosis and treatment of fetal and pediatric age patients (0-12 years) with Wolff-Parkinson-White syndrome and atrioventricular accessory pathways[J]. J Cardiovasc Med (Hagerstown),2023,24(9):589-601.
[4] Lim YT,Kim YH,Kwon JE. Effective control of supraventricular tachycardia in neonates may requires combination pharmacologic therapy[J]. J Clin Med,2022,11(12):3279.
[5] Chambers S,Jnah A,Newberry D. The pathophysiology,diagnosis,and management of Wolff-Parkinson-White syndrome in the neonate[J]. Adv Neonatal Care,2021,21(3):178-188.?
[6] 罗刚,纪志娴,江倩男,等. 新生儿无结构性心脏病阵发性室上性心动过速的临床特点和结局. 中华围产医学杂志,2024,27(6):484-489.
[7] Peng G,Zei PC. Diagnosis and management of paroxysmal supraventricular tachycardia[J]. JAMA,2024,331(7):601-610.
[8] Bruder D,Weber R,Gass M,et al. Antiarrhythmic medication in neonates and infants with supraventricular tachycardia[J]. Pediatr Cardiol,2022,43(6):1311-1318.
[9] Philip Saul J,Kanter RJ; WRITING COMMITTEE,et al. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease:developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES,HRS,the American Academy of Pediatrics (AAP),the American Heart Association (AHA),and the Association for European Pediatric and Congenital Cardiology (AEPC)[J]. Heart Rhythm,2016,13(6):e251-e289.?
[10] O’Leary ET,Alexander ME,Bezzerides VJ,et al. Low mortality in fetal supraventricular tachycardia:outcomes in a 30-year single-institution experience[J]. J Cardiovasc Electrophysiol,2020,31(5):1105-1113.?
[11] Moore JA,Stephens SB,Kertesz NJ,et al. Clinical predictors of recurrent supraventricular tachycardia in infancy[J]. J Am Coll Cardiol,2022,80(12):1159-1172.?
[12] Mecklin M,Linnanm?ki A,Hiippala A,et al Multicenter cohort study on duration of antiarrhythmic medication for supraventricular tachycardia in infants[J]. Eur J Pediatr,2023,182(3):1089-1097.?
[13] Pompa AG,LaPage MJ. Outcomes of infant supraventricular tachycardia management without medication[J]. Pediatr Cardiol,2024,45(8):1724-1728.
[14] Tortoriello TA,Snyder CS,Smith EO,et al. Frequency of recurrence among infants with supraventricular tachycardia and comparison of recurrence rates among those with and without preexcitation and among those with and without response to digoxin and/or propranolol therapy[J]. Am J Cardiol,2003,92(9):1045-1049.
[15] Vari D,Kurek N,Zang H,et al. Outcomes in infants with supraventricular tachycardia: risk factors for readmission,recurrence and ablation[J]. Pediatr Cardiol,2024,45(6):1211-1220.
[16] Kanter RJ. Care of the infant with supraventricular tachycardia:toward a better paradigm[J]. J Am Coll Cardiol,2022,80(12):1173-1176.
[17] Drago F,Silvetti MS,De Santis A,et al. Paroxysmal reciprocating supraventricular tachycardia in infants: electrophysiologically guided medical treatment and long-term evolution of the re-entry circuit[J]. Europace,2008,10(5):629-635.
[18] Ciriello GD,Colonna D,Papaccioli G,et al. Triple antiarrhythmic therapy in newborns with refractory atrioventricular reentrant tachycardia[J]. Pediatr Cardiol,2023,44(5):1040-1049.
[19] Ergül Y,Sulu A,?aran B,et al. Clinical course and electrophysiological characteristics of permanent junctional reciprocating tachycardia in children[J]. Anatol J Cardiol,2022,26(12):880-885.
[20] Sanatani S,Hamilton RM,Gross GJ. Predictors of refractory tachycardia in infants with supraventricular tachycardia[J]. Pediatr Cardiol,2002,23(5):508-512.
[21] Chu PY,Hill KD,Clark RH,et al. Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database[J]. Early Hum Dev,2015,91(6):345-350.?
[22] Capponi G,Belli G,Giovannini M,et al. Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24?years of experience in a single centre[J]. BMC Cardiovasc Disord,2021,21(1):137.?
[23] P?rregaard MM,Hartmann J,Sillesen AS,et al. The Wolff-Parkinson-White pattern in neonates:results from a large population-based cohort study[J]. Europace,2023,25(7):euad165.
[24] Salerno JC,Garrison MM,Larison C,et al. Case fatality in children with supraventricular tachycardia in the United States[J]. Pacing Clin Electrophysiol,2011,34(7):832-836.?
[25] Barton AL,Moffett BS,Valdes SO,et al. Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrhythmias[J]. J Pediatr,2015,166(1):115-118.?
[26] Wei N,Lamba A,Franciosi S,et al. Medical management of infants with supraventricular tachycardia: results from a registry and review of the literature[J]. CJC Pediatr Congenit Heart Dis,2022,1(1):11-22.?
[27] Garson A Jr,Gillette PC,McNamara DG. Supraventricular tachycardia in children: clinical features,response to treatment,and long-term follow-up in 217 patients[J]. J Pediatr,1981,98(6):875-882.
[28] Brugada J,Blom N,Sarquella-Brugada G,et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement[J]. Europace,2013,15(9):1337-1382.?
[29] Wong KK,Potts JE,Etheridge SP,et al. Medications used to manage supraventricular tachycardia in the infant a North American survey[J]. Pediatr Cardiol,2006,27(2):199-203.?
[30] Sanatani S,Potts JE,Reed JH,et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter,randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants[J]. Circ Arrhythm Electrophysiol,2012,5(5):984-991.?
[31] Aljohani OA,Herrick NL,Borquez AA,et al. Antiarrhythmic treatment duration and tachycardia recurrence in infants with supraventricular tachycardia[J]. Pediatr Cardiol,2021,42(3):716-720.

备注/Memo

备注/Memo:
收稿日期：2024-11-04
更新日期/Last Update: 2025-05-16